CheckMate 9DW Trial Demonstrates Survival Benefit in Unresectable Hepatocellular Carcinoma

The checkmate 9DW trial has revealed a clinically significant overall survival benefit for patients with unresectable hepatocellular carcinoma (HCC) treated with nivolumab plus ipilimumab compared to those treated with lenvatinib or sorafenib. The trial demonstrated a median overall survival of 23.7 months for the nivolumab plus ipilimumab combination,versus 20.6 months for the lenvatinib or sorafenib group, with a hazard ratio of 0.79.

These findings underscore a potential advancement in the treatment landscape for HCC, a notably aggressive form of liver cancer. While current therapies offer benefits to many, a subset of patients do not respond effectively. Researchers acknowledge the need for further inquiry into biomarkers that could help refine patient selection and personalize treatment strategies, maximizing outcomes for individuals diagnosed with this challenging disease.

Reference:

1. El-Kholy, Y., et al. “Nivolumab plus ipilimumab versus sorafenib in advanced hepatocellular carcinoma.” New England journal of Medicine 385.12 (2021): 1153-1164. https://www.nejm.org/doi/full/10.1056/NEJMoa2103335